Ongoing treatment(s)-Hormonal therapy - Page 4 of 12 Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Hormonal therapy Posts on Medivizor

Apalutamide does not affect health-related quality of life in patients with localized prostate cancer

Apalutamide does not affect health-related quality of life in patients with localized prostate cancer

Posted by on Nov 28, 2018 in Prostate cancer | 0 comments

In a nutshell This study investigated the effect of apalutamide (Erleada) on health-related quality of life (H-QoL) in patients with prostate cancer. This study found that apalutimide preserved H-QoL while prolonging time taken for cancer to spread.  Some background One treatment option for patients with prostate cancer is androgen...

Read More

Evaluating optimal duration of androgen deprivation therapy in high risk prostate cancer

Evaluating optimal duration of androgen deprivation therapy in high risk prostate cancer

Posted by on Nov 25, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the effect of the length of androgen deprivation therapy (ADT) when used with radiotherapy in patients with prostate cancer. This study found that 18 months ADT led to similar overall survival and better quality of life as compared to 36 months in these patients.  Some background...

Read More

Comparing two hormone therapy drugs in men with advanced, non-metastatic prostate cancer

Posted by on Nov 17, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to compare two hormone therapies, gonadotropin-releasing hormone (GnRH) agonists and anti-androgen therapy (AA) in men with advanced, non-metastatic prostate cancer. This study found that the two therapies have similar outcomes, but by starting with AA treatment may reduce side effects associated with GnRH...

Read More

10 years of treatment vs 5 years of treatment with hormone therapy in patients with early stage breast cancer.

10 years of treatment vs 5 years of treatment with hormone therapy in patients with early stage breast cancer.

Posted by on Oct 22, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if continuing hormone therapy for 10 years was more effective than doing it for 5 years in patients with early stage breast cancer. The study found that the patients who continued treatment for 10 years survived for longer without the disease coming back compared to those who were only treated for 5...

Read More

Should men with castration-resistant metastatic prostate cancer receive further hormone therapy?

Should men with castration-resistant metastatic prostate cancer receive further hormone therapy?

Posted by on Aug 21, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to discover the optimal timing of hormone therapies in combination with androgen-deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer. This study found that treatment with a second hormone therapy after prostate cancer becomes immune to hormone treatment is associated...

Read More

Fulvestrant compared to aromatase inhibitors in post-menopausal women with HR+ advanced breast cancer

Fulvestrant compared to aromatase inhibitors in post-menopausal women with HR+ advanced breast cancer

Posted by on Jul 16, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to look at the safety and effectiveness of fulvestrant (Faslodex) compared to aromatase inhibitors in post-menopausal women with hormone receptor-positive (HR+) breast cancer. The authors found that fulvestrant was a safe and effective treatment in these patients when compared to aromatase inhibitors. Some...

Read More

Comparison of lapatinib and trastuzumab in patients with HER-2 receptor positive breast cancer

Comparison of lapatinib and trastuzumab in patients with HER-2 receptor positive breast cancer

Posted by on Jul 2, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to compare lapatinib (Tykerb) and trastuzumab (Herceptin) in patients with HER-2 receptor positive breast cancer. This study found that in patients with hormone receptor-positive tumors, use of lapatinib for 6 months, followed by trastuzumab for 12 months significantly improved survival...

Read More

Exercise, body composition and fatigue with androgen deprivation therapy

Exercise, body composition and fatigue with androgen deprivation therapy

Posted by on May 22, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to determine whether body composition (lean and fat mass) and exercise had an effect on fatigue levels in men treated with androgen deprivation therapy. The study concluded that fat mass was associated with fatigue, and an increase in lean mass due to exercise successfully reduced fatigue. Some background Androgen...

Read More